Oxford BioMedica (OXB) Stock Statistics & Valuation Metrics

Oxford BioMedica has a market cap or net worth of £741.68M. The enterprise value is 387.11M.

Oxford BioMedica has 120,206,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oxford BioMedica’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -23.33%.

The current PE Ratio of Oxford BioMedica is ―. Oxford BioMedica’s PEG ratio is 0.14.

In the last 12 months, Oxford BioMedica had revenue of 128.80M and earned -43.19M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -9.50M and capital expenditures -4.19M, giving a free cash flow of -13.69M billion.

Oxford BioMedica pays an annual dividend of ―, resulting in a dividend yield of ―

Oxford BioMedica upcoming earnings date is Sep 23, 2025, TBA (Confirmed).

Oxford BioMedica as a current ratio of 2.28, with Debt / Equity ratio of 190.65%

In the past 12 months, Oxford BioMedica has paid 1.34M in taxes.

Oxford BioMedica EV to EBITDA ratio is -33.67, with an EV/FCF ratio of -8.30.

Oxford BioMedica has £53.88M in cash and marketable securities with £105.42M in debt, giving a net cash position of -£51.55M billion.

Gross margin is 40.90%, with operating margin of -30.57%, and net profit margin of -33.53%.

The average price target for Oxford BioMedica is £639.96, which is 11.43% higher than the current price. The consensus rating is Strong Buy